Literature DB >> 31113730

Melittin - A bee venom component - Enhances muscle regeneration factors expression in a mouse model of skeletal muscle contusion.

Jae Eun Lee1, Vikash Kumar Shah2, Eun-Jung Lee3, Min-Seok Oh4, Jeong June Choi5.   

Abstract

Melittin is a major peptide component of sweet bee venom that possesses anti-allergic, anti-inflammatory, anti-arthritis, anti-cancer, and neuroprotective properties. However, the therapeutic effects of melittin on muscle injury have not been elucidated. We investigated the therapeutic effects of melittin on muscle injury in a mouse model of muscle contusion. The biceps femoris muscle of the mice was injured using drop mass method, and the animals were treated with melittin (4, 20, or 100 μg/kg) for 7 days. Melittin significantly increased: locomotor activity in open field test, and treadmill running activity in a dose-dependent manner to level comparable to the positive control, diclofenac (30 mg/kg). Melittin treatment attenuated the pro-inflammatory cytokine MCP-1, TNF-α and IL-6. The expression of muscle regeneration biomarkers, including MyoD (muscle differentiation marker), myogenin, smooth muscle actin, and myosin heavy chain was markedly increased in the injured muscle tissue of melittin-treated mice, as determined by western blotting and quantitative real-time polymerase chain reaction. These results demonstrate that melittin inhibits inflammatory response and improves muscle damage by regenerating muscles in a mouse model of muscle contusion. Taken together, the results of present study suggest that melittin is a promising candidate for the muscle injury treatment.
Copyright © 2019 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory effects; Melittin; Muscle contusion; Muscle regeneration; Sweet bee venom

Mesh:

Substances:

Year:  2019        PMID: 31113730     DOI: 10.1016/j.jphs.2019.03.009

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  7 in total

Review 1.  Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective.

Authors:  Peiying Shi; Shihui Xie; Jiali Yang; Yi Zhang; Shuo Han; Songkun Su; Hong Yao
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

2.  Myoblast deactivation within engineered human skeletal muscle creates a transcriptionally heterogeneous population of quiescent satellite-like cells.

Authors:  Jason Wang; Torie Broer; Taylor Chavez; Chris J Zhou; Sabrina Tran; Yu Xiang; Alastair Khodabukus; Yarui Diao; Nenad Bursac
Journal:  Biomaterials       Date:  2022-04-07       Impact factor: 15.304

Review 3.  Mitochondria-cytokine crosstalk following skeletal muscle injury and disuse: a mini-review.

Authors:  Anita E Qualls; W Michael Southern; Jarrod A Call
Journal:  Am J Physiol Cell Physiol       Date:  2021-02-10       Impact factor: 4.249

4.  Mechanism of antimicrobial activity of honeybee (Apis mellifera) venom on Gram-negative bacteria: Escherichia coli and Pseudomonas spp.

Authors:  Izlem Haktanir; Maria Masoura; Fani Th Mantzouridou; Konstantinos Gkatzionis
Journal:  AMB Express       Date:  2021-04-09       Impact factor: 3.298

Review 5.  Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy.

Authors:  Tenzin Tender; Rakesh Ravishankar Rahangdale; Sridevi Balireddy; Madhavan Nampoothiri; K Krishna Sharma; Hariharapura Raghu Chandrashekar
Journal:  Med Oncol       Date:  2021-04-02       Impact factor: 3.064

Review 6.  Bee Venom: An Updating Review of Its Bioactive Molecules and Its Health Applications.

Authors:  Maria Carpena; Bernabe Nuñez-Estevez; Anton Soria-Lopez; Jesus Simal-Gandara
Journal:  Nutrients       Date:  2020-10-31       Impact factor: 5.717

7.  Chemical, Cytotoxic, and Anti-Inflammatory Assessment of Honey Bee Venom from Apis mellifera intermissa.

Authors:  Iouraouine El Mehdi; Soraia I Falcão; Mustapha Harandou; Saïd Boujraf; Ricardo C Calhelha; Isabel C F R Ferreira; Ofélia Anjos; Maria G Campos; Miguel Vilas-Boas
Journal:  Antibiotics (Basel)       Date:  2021-12-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.